robot ortho surgeri reiter
outperform top pick up tp
mako surg stand drive stronger expect
organ growth vs cs estimate driven surg
vs ortho vs partial off-set neurotech/spin
vs bottom line upsid sale lower sg
 partial off-set higher unfavor
tax lower non-op incom deliv upsid rel
ep estim given somewhat temper investor expect
quarter expect stock react favor upsid reiter
outperform rate rais tp
new robot y/i ww implant sequenti
 robot beat estimate vs new ou robot grew
y/i importantli util mako volum acceler
sequenti total knee sequenti y/i
expect tailwind new robot continu drive implant share gain
op mgn line y/i surg mix fx weigh gm
gm impact tougher fx higher growth surg
lower gm roughli neutral op mgn guidanc organ
sale growth ep better expect
valuat target price base previous
ebitda bil risk integr recent
acquisit delay key product failur progress lt goal chang
competit landscap robot surgeri potenti new litig
regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
stryker corp global manufactur provid medic
devic equip treatment musculoskelet
patient care
price jan rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
one-year valuat scenario base
ev/ebitda ebitda
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base high-growth segment grow
growth grow
mil
mil y/i
addit detail takeaway
sale cc organ driven increas unit volum
partial off-set lower price
us knee sale mil mil increas ou knee sale mil
us hip sale mil mil increas off-set ou hip sale
trauma extrem mil mil y/i cc
us trauma extrem sale mil in-lin increas ou trauma
extrem sale mil mil increas cc
us sale mil mil increas ou sale mil
mil increas cc drive higher expect robot sale greater
proport robot sale form capit purchas vs oper leas posit
robot price-mix driven larger portion robot includ total knee applic
increas mainten revenu driven expand instal base robot
quarter compani place mako robot ww estim
robot ww competit account us compani place
robot quarter vs estim ww basi compani
robot instal quarter compani certifi
surgeon total knee applic bring total number surgeon
train sinc launch approxim robot procedur perform
 full year mako procedur mako total knee
procedur increas sequenti knee repres
mako procedur perform util rate robot
measur end prior quarter grew sequenti
medsurg bil mil y/i cc organ
sale cc organ driven includ
increas unit volum partial off-set lower price
us instrument sale mil mil increas ou instrument sale
mil mil increas cc
us endoscopi sale mil mil increas ou endoscopi sale
sale mil mil increas ou endoscopi sale
mil mil increas cc physiocontrol sale dd
us sustain sale mil in-lin increas ou sustain sale
mil y/i
mil y/i
in-lin y/i
in-lin y/i
neurotech spine mil mil y/i cc
mil
mil y/i
sale cc organ driven includ
increas unit volum partial off-set lower price
us neurotech sale mil mil increas ou neurotech sale
us spine sale mil mil increas ou spine sale mil
 oper margin in-lin estim bp y/i
bottom line upsid sale lower sg
partial off-set higher unfavor tax lower non-op incom
deliv ep estim consensu gross margin
bp estim bp last year quarter gm
favor impact off-set product mix higher sale
surg product price fx price quarter compani
expect price pressur consist
sale
sale
sale
sale
estimate
ep
compani guid organ sale growth ep guidanc
compani expect neg fx impact
estimate
charl martineau pm univers toronto figur chang model
chang model
rais sale estim ep reflect
manag guidanc beyond also rais revenu estim
rais ep estim year beyond
previous target price base previous
ebitda bil previous bil lower multipl in-lin stock
current trade multipl de-rat sinc decemb risk execut
issu relat recent acquisit key product delay failur progress lt goal
chang competit landscap robot surgeri potenti new litig
regulatori qualiti issu
charl martineau pm univers toronto compani mention price
